Manufacturers Respond To AARP Concerns On Pricing, But Decline To Take Pledge
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck, GSK, Lilly and PhRMA will not voluntarily limit price increases as AARP requested. The tone of the responses, the seniors' group noted, has been cooperative. Several manufacturers suggested a meeting with AARP as the next step.
You may also be interested in...
AARP “Rx Watchdog Report” Will Analyze Price Increases Ahead Of Medicare Discount Cards
The new publication series kicks off with a study on brand name drug price increases by manufacturers from 2000-2003. showing WAC for widely used brand drugs rose an average of 23.6% versus cumulative inflation of 10.4%. “Watchdog” reports on generic drug and first quarter 2004 price hikes are in the pipeline.
AARP “Rx Watchdog Report” Will Analyze Price Increases Ahead Of Medicare Discount Cards
The new publication series kicks off with a study on brand name drug price increases by manufacturers from 2000-2003. showing WAC for widely used brand drugs rose an average of 23.6% versus cumulative inflation of 10.4%. “Watchdog” reports on generic drug and first quarter 2004 price hikes are in the pipeline.
Misleading Drug Ads Should Be Subject To Financial Penalties, AARP Says
Congress should implement financial penalties for misleading drug ads, AARP Executive Director for State & National Initiatives Christopher Hansen said